» Articles » PMID: 27176184

Overactive Bladder - 18 Years - Part I

Abstract

Overactive bladder syndrome is one of the lower urinary tract dysfunctions with the highest number of scientific publications over the past two decades. This shows the growing interest in better understanding this syndrome, which gathers symptoms of urinary urgency and increased daytime and nighttime voiding frequency, with or without urinary incontinence and results in a negative impact on the quality of life of approximately one out of six individuals - including both genders and almost all age groups. The possibility of establishing the diagnosis just from clinical data made patients' access to specialized care easier. Physiotherapy resources have been incorporated into the urological daily practice. A number of more selective antimuscarinic drugs with consequent lower adverse event rates were released. Recently, a new class of oral drugs, beta-adrenergic agonists has become part of the armamentarium for Overactive Bladder. Botulinum toxin injections in the bladder and sacral neuromodulation are routine modalities of treatment for refractory cases. During the 1st Latin-American Consultation on Overactive Bladder, a comprehensive review of the literature related to the evolution of the concept, epidemiology, diagnosis, and management was conducted. This text corresponds to the first part of the review Overactive Bladder 18-years.

Citing Articles

Efficacy and safety of TURP, HoLEP, and PVP in the management of OAB symptoms complicating BPH in patients with moderately enlarged prostates: A comparative study.

Mostafa M, Khallaf A, Khalil M, Elgammal M, Mahdy A Can Urol Assoc J. 2022; 17(1):E1-E7.

PMID: 36121889 PMC: 9872828. DOI: 10.5489/cuaj.7905.


TGR5 agonists induce peripheral and central hypersensitivity to bladder distension.

Caldwell A, Grundy L, Harrington A, Garcia-Caraballo S, Castro J, Bunnett N Sci Rep. 2022; 12(1):9920.

PMID: 35705684 PMC: 9200837. DOI: 10.1038/s41598-022-14195-w.


Update on the management of overactive bladder.

Fontaine C, Papworth E, Pascoe J, Hashim H Ther Adv Urol. 2021; 13:17562872211039034.

PMID: 34484427 PMC: 8411623. DOI: 10.1177/17562872211039034.


New Implantable Tibial Nerve Stimulation Devices: Review of Published Clinical Results in Comparison to Established Neuromodulation Devices.

Yamashiro J, de Riese W, de Riese C Res Rep Urol. 2020; 11:351-357.

PMID: 31921712 PMC: 6934123. DOI: 10.2147/RRU.S231954.


Mechanisms Underlying Overactive Bladder and Interstitial Cystitis/Painful Bladder Syndrome.

Grundy L, Caldwell A, Brierley S Front Neurosci. 2019; 12:931.

PMID: 30618560 PMC: 6299241. DOI: 10.3389/fnins.2018.00931.

References
1.
Fitzgerald M, Ayuste D, Brubaker L . How do urinary diaries of women with an overactive bladder differ from those of asymptomatic controls?. BJU Int. 2005; 96(3):365-7. DOI: 10.1111/j.1464-410X.2005.05632.x. View

2.
Liu H, Tyagi P, Chancellor M, Kuo H . Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int. 2009; 106(11):1681-5. DOI: 10.1111/j.1464-410X.2009.08851.x. View

3.
Milsom I, Stewart W, Thuroff J . The prevalence of overactive bladder. Am J Manag Care. 2001; 6(11 Suppl):S565-73. View

4.
Kim J, Park E, Hong S, Seo S, Park Y, Hwang T . Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int J Urol. 2005; 12(10):875-80. DOI: 10.1111/j.1442-2042.2005.01140.x. View

5.
OReilly B, Fynes M, Achtari C, Hiscock R, Thomas E, Murray C . A prospective randomised double-blind controlled trial evaluating the effect of trans-sacral magnetic stimulation in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2007; 19(4):497-502. DOI: 10.1007/s00192-007-0481-y. View